**Supplementary Figure S1.** Blood glucose levels during treatment. **(a)** Weekly measured blood glucose levels starting after treatment (means ± SD). **(b)** Blood glucose change. C, Control (n=13); D, Diabetic (n=17); SV, Sacubitril/valsartan treated diabetic (n=16); V, Valsartan treated diabetic (n=15); each data point is one animal.

Supplementary Figure S2. Time course blood glucose levels during OGTT. C, Control (n=8); D, Diabetic (n=7); SV, Sacubitril/valsartan treated diabetic (n=8); V, Valsartan treated diabetic (n=9); values show as means ± SD.

Supplementary Table S1. Blood glucose levels at each time point during OGTT
C, Control (n=8); D, Diabetic (n=7); SV, Sacubitril/valsartan treated diabetic (n=8); V, V, Valsartan treated diabetic (n=9). ****, p<0.0001 compared to control. Values shown as means ± SD.

|	C (n=8)	D (n=7)	SV (n=8)	V (n=9)
0. min BG (mg/dL)	102.38 ± 7.95	354.71 ± 29.25****	362.13 ± 24.19	381.33 ± 50.14
30. min BG (mg/dL)	128.88 ± 10.36	536.86 ± 53.06****	536.13 ± 36.72	542.00 ± 63.31
60. min BG (mg/dL)	124.13 ± 13.16	529.14 ± 68.54****	507.25 ± 45.60	549.11 ± 60.58
90. min BG (mg/dL)	110.13 ± 12.81	524.86 ± 89.11****	513.88 ± 40.02	523.00 ± 63.04
120. min BG (mg/dL)	114.63 ± 25.49	482.57 ± 90.48****	460.13 ± 25.96	491.22 ± 85.40
180. min BG (mg/dL)	109.88 ± 18.94	444.00 ± 79.86****	469.13 ± 41.35	487.33 ± 88.40

Supplementary Table S2. Fasting blood glucose and insulin levels prior to OGTT and HOMA-IR values
C, Control (n=5); D, Diabetic (n=5); SV, Sacubitril/valsartan treated diabetic (n=6); V, Valsartan treated diabetic (n=5). ****, p<0.0001 compared to control. Values shown as means ± SD,

	C (n=5)	D (n=5)	SV (n=6)	V (n=5)
Fasting blood glucose (mg/dL)	102.00 ± 8.34	350.40 ± 27.49****	365.00 ± 24.39	400.20 ± 62.54
Fasting insulin (mIU/L)	10.21 ± 0.77	10.77 ± 0.96	10.30 ± 0.86	10.36 ± 0.63
HOMA-IR	2.56 ± 0.20	9.27 ± 0.45****	9.29 ± 1.18	10.22 ± 1.74

Supplementary Figure S3. Plasma lipid levels. **(a)** Total cholesterol levels. **(b)** Triglyceride levels. C, Control (n=13); D, Diabetic (n=9); SV, Sacubitril/valsartan treated diabetic (n=12); V, Valsartan treated diabetic (n=12). *, $p<0.05$; ***, $p<0.001$ compared to control. Each data point represents one animal.

Supplementary Figure S4. GAPDH validation as a housekeeping gene. C, Control (n=5); D, Diabetic (n=5); SV, Sacubitril/valsartan treated diabetic (n=5); V; Valsartan treated diabetic (n=4). Each datapoint represents one animal.